Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.

Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators.

Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.

2.

Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes.

Casanova N, Zhou T, Gonzalez-Garay ML, Rosas IO, Goldberg HJ, Ryter SW, Collard HR, El-Chemaly S, Flaherty KR, Hunninghake GM, Lasky JA, Lederer DJ, Machado RF, Martinez FJ, Noth I, Raghu G, Choi AMK, Garcia JGN.

Sci Rep. 2019 Oct 15;9(1):14802. doi: 10.1038/s41598-019-50585-3.

3.

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G.

Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28.

PMID:
31575509
4.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

PMID:
31566307
5.

99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis.

Flaherty KR, Morgenstern R, Pozniakoff T, DeLuca A, Castano A, Maurer MS, Bokhari S.

J Nucl Cardiol. 2019 Aug 28. doi: 10.1007/s12350-019-01831-8. [Epub ahead of print]

PMID:
31463816
6.

Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity.

Richeldi L, Cottin V, Brown KK, Flaherty KR, Johannson KA, Travis WD, Collard HR.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):941-942. doi: 10.1164/rccm.201905-0932LE. No abstract available.

7.

Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis.

Dickson RP, Huffnagle GB, Flaherty KR, White ES, Martinez FJ, Erb-Downward JR, Moore BB, O'Dwyer DN.

Am J Respir Crit Care Med. 2019 Dec 15;200(12):1544-1547. doi: 10.1164/rccm.201903-0680LE. No abstract available.

8.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

9.

Patient Registries in Idiopathic Pulmonary Fibrosis.

Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

10.

The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.

Richeldi L, Launders N, Martinez F, Walsh SLF, Myers J, Wang B, Jones M, Chisholm A, Flaherty KR.

ERJ Open Res. 2019 Apr 1;5(2). pii: 00209-2018. doi: 10.1183/23120541.00209-2018. eCollection 2019 Apr.

11.

Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study.

Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TV, Myers JL, Groshong SD, Larsen BT, Chung JH, Steele MP, Benzaquen S, Calero K, Case AH, Criner GJ, Nathan SD, Rai NS, Ramaswamy M, Hagmeyer L, Davis JR, Gauhar UA, Pankratz DG, Choi Y, Huang J, Walsh PS, Neville H, Lofaro LR, Barth NM, Kennedy GC, Brown KK, Martinez FJ.

Lancet Respir Med. 2019 Jun;7(6):487-496. doi: 10.1016/S2213-2600(19)30059-1. Epub 2019 Apr 1.

PMID:
30948346
12.

Pulmonary fibrosis: "idiopathic" is not "cryptogenic".

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Mar 18;53(3). pii: 1900400. doi: 10.1183/13993003.00400-2019. Print 2019 Mar. No abstract available.

PMID:
30886028
13.

Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis.

Sheth JS, Xia M, Murray S, Martinez CH, Meldrum CA, Belloli EA, Salisbury ML, White ES, Holtze CH, Flaherty KR.

Respir Med. 2019 Mar;148:6-12. doi: 10.1016/j.rmed.2019.01.008. Epub 2019 Jan 24.

14.

Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.

O'Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB, Salisbury ML, Han MK, Flaherty KR, White ES, Martinez FJ, Erb-Downward JR, Murray S, Moore BB, Dickson RP.

Am J Respir Crit Care Med. 2019 May 1;199(9):1127-1138. doi: 10.1164/rccm.201809-1650OC.

PMID:
30789747
15.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Feb 14;53(2). pii: 1801939. doi: 10.1183/13993003.01939-2018. Print 2019 Feb. No abstract available.

PMID:
30765483
16.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

17.

The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis.

Flores RJ, Flaherty KR, Jin Z, Bokhari S.

J Nucl Cardiol. 2018 Nov 12. doi: 10.1007/s12350-018-01504-y. [Epub ahead of print]

PMID:
30421379
18.

Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory.

Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, Kazerooni EA, Myers JL, Lagstein A, Konopka KE, Belloli EA, Sheth JS, White ES, Holtze C, Martinez FJ, Flaherty KR.

Chest. 2019 Apr;155(4):699-711. doi: 10.1016/j.chest.2018.08.1076. Epub 2018 Sep 19.

PMID:
30243979
19.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
20.

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA.

Eur Respir J. 2018 Sep 17;52(3). pii: 1801384. doi: 10.1183/13993003.01384-2018. Print 2018 Sep.

PMID:
30139770
21.

Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.

Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR.

Lancet Respir Med. 2018 Sep;6(9):707-714. doi: 10.1016/S2213-2600(18)30301-1. Epub 2018 Aug 9.

PMID:
30100404
22.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

23.

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.

Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L.

Eur Respir J. 2018 Aug 2;52(2). pii: 1702593. doi: 10.1183/13993003.02593-2017. Print 2018 Aug.

24.

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

Flaherty KR, Fell CD, Huggins JT, Nunes H, Sussman R, Valenzuela C, Petzinger U, Stauffer JL, Gilberg F, Bengus M, Wijsenbeek M.

Eur Respir J. 2018 Aug 2;52(2). pii: 1800230. doi: 10.1183/13993003.00230-2018. Print 2018 Aug. Erratum in: Eur Respir J. 2018 Oct 4;52(4):.

25.

Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis.

Salisbury ML, Gross BH, Chughtai A, Sayyouh M, Kazerooni EA, Bartholmai BJ, Xia M, Murray S, Myers JL, Lagstein A, Konopka KE, Belloli EA, Sheth JS, White ES, Holtze C, Martinez FJ, Flaherty KR.

Eur Respir J. 2018 Aug 16;52(2). pii: 1800443. doi: 10.1183/13993003.00443-2018. Print 2018 Aug.

26.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May. Review.

27.

Reply to Fernández Pérez: Diagnostic Decision-Making in Hypersensitivity Pneumonitis: Toward a Consensus Statement.

Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1647-1648. doi: 10.1164/rccm.201801-0125LE. No abstract available.

28.

Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and Reproducibility.

Kennedy GC, Barth NM, Walsh PS, Huang J, Pankratz DG, Choi Y, Fedorowicz GM, Anderson JD, Raghu G, Martinez FJ, Colby TV, Lynch DA, Brown KK, Groshong SD, Myers JL, Flaherty KR, Steele MP.

Ann Am Thorac Soc. 2017 Dec;14(12):1864-1865. doi: 10.1513/AnnalsATS.201708-654LE. No abstract available.

PMID:
29058451
29.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

30.

Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients.

Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, Kazerooni EA, Sundaram B, Chughtai AR, Martinez FJ, Flaherty KR.

Respir Med. 2017 Oct;131:229-235. doi: 10.1016/j.rmed.2017.08.025. Epub 2017 Sep 12.

31.

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

Parker JM, Glaspole IN, Lancaster LH, Haddad TJ, She D, Roseti SL, Fiening JP, Grant EP, Kell CM, Flaherty KR.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):94-103. doi: 10.1164/rccm.201704-0784OC.

PMID:
28787186
32.

Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.

O'Dwyer DN, Norman KC, Xia M, Huang Y, Gurczynski SJ, Ashley SL, White ES, Flaherty KR, Martinez FJ, Murray S, Noth I, Arnold KB, Moore BB.

Sci Rep. 2017 Jun 30;7:46860. doi: 10.1038/srep46860.

33.

Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning.

Pankratz DG, Choi Y, Imtiaz U, Fedorowicz GM, Anderson JD, Colby TV, Myers JL, Lynch DA, Brown KK, Flaherty KR, Steele MP, Groshong SD, Raghu G, Barth NM, Walsh PS, Huang J, Kennedy GC, Martinez FJ.

Ann Am Thorac Soc. 2017 Nov;14(11):1646-1654. doi: 10.1513/AnnalsATS.201612-947OC.

PMID:
28640655
34.

Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up.

Humphries SM, Yagihashi K, Huckleberry J, Rho BH, Schroeder JD, Strand M, Schwarz MI, Flaherty KR, Kazerooni EA, van Beek EJR, Lynch DA.

Radiology. 2017 Oct;285(1):270-278. doi: 10.1148/radiol.2017161177. Epub 2017 May 10.

35.

Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.

Martinez FJ, Flaherty KR.

Chest. 2017 May;151(5):1173-1174. doi: 10.1016/j.chest.2017.03.017.

PMID:
28483105
36.

The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.

O'Dwyer DN, Norman KC, Xia M, Huang Y, Gurczynski SJ, Ashley SL, White ES, Flaherty KR, Martinez FJ, Murray S, Noth I, Arnold KB, Moore BB.

Sci Rep. 2017 Apr 25;7:46560. doi: 10.1038/srep46560. Erratum in: Sci Rep. 2017 Jun 30;7:46860.

37.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP. No abstract available.

38.

Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Huang Y, Ma SF, Espindola MS, Vij R, Oldham JM, Huffnagle GB, Erb-Downward JR, Flaherty KR, Moore BB, White ES, Zhou T, Li J, Lussier YA, Han MK, Kaminski N, Garcia JGN, Hogaboam CM, Martinez FJ, Noth I; COMET-IPF Investigators.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):208-219. doi: 10.1164/rccm.201607-1525OC.

39.

Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):690-699. doi: 10.1164/rccm.201608-1675PP. Review. No abstract available.

40.

Decreased Lung Perfusion After Breast/Chest Wall Irradiation: Quantitative Results From a Prospective Clinical Trial.

Liss AL, Marsh RB, Kapadia NS, McShan DL, Rogers VE, Balter JM, Moran JM, Brock KK, Schipper MJ, Jagsi R, Griffith KA, Flaherty KR, Frey KA, Pierce LJ.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):296-302. doi: 10.1016/j.ijrobp.2016.10.012. Epub 2016 Oct 19.

41.

The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, Walsh SL, White ES, Richeldi L.

Lancet Respir Med. 2017 Jan;5(1):61-71. doi: 10.1016/S2213-2600(16)30325-3. Epub 2016 Dec 6. Review.

42.

Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.

Salisbury ML, Lynch DA, van Beek EJ, Kazerooni EA, Guo J, Xia M, Murray S, Anstrom KJ, Yow E, Martinez FJ, Hoffman EA, Flaherty KR; IPFnet Investigators.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):921-929. doi: 10.1164/rccm.201607-1385OC.

43.

Utility of Transbronchial vs Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease.

Sheth JS, Belperio JA, Fishbein MC, Kazerooni EA, Lagstein A, Murray S, Myers JL, Simon RH, Sisson TH, Sundaram B, White ES, Xia M, Zisman D, Flaherty KR.

Chest. 2017 Feb;151(2):389-399. doi: 10.1016/j.chest.2016.09.028. Epub 2016 Oct 8.

44.

Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Callahan SJ, Xia M, Murray S, Flaherty KR.

Respir Med. 2016 Oct;119:96-101. doi: 10.1016/j.rmed.2016.08.028. Epub 2016 Aug 31.

45.

Clinical Trial Design Based on Time to Death/Progression.

Murray S, Flaherty KR.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):653-4. doi: 10.1164/rccm.201604-0819ED. No abstract available.

PMID:
27628074
46.

Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling.

Salisbury ML, Xia M, Murray S, Bartholmai BJ, Kazerooni EA, Meldrum CA, Martinez FJ, Flaherty KR.

Respir Med. 2016 Sep;118:88-95. doi: 10.1016/j.rmed.2016.07.016. Epub 2016 Jul 28.

47.

Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF.

Ashley SL, Xia M, Murray S, O'Dwyer DN, Grant E, White ES, Flaherty KR, Martinez FJ, Moore BB.

PLoS One. 2016 Aug 4;11(8):e0159878. doi: 10.1371/journal.pone.0159878. eCollection 2016.

48.

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):78-85. doi: 10.1164/rccm.201602-0402OC.

49.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ.

Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. Review.

50.

Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study.

Walsh SLF, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, Nunes H, Valeyre D, Brillet PY, Kambouchner M, Morais A, Pereira JM, Moura CS, Grutters JC, van den Heuvel DA, van Es HW, van Oosterhout MF, Seldenrijk CA, Bendstrup E, Rasmussen F, Madsen LB, Gooptu B, Pomplun S, Taniguchi H, Fukuoka J, Johkoh T, Nicholson AG, Sayer C, Edmunds L, Jacob J, Kokosi MA, Myers JL, Flaherty KR, Hansell DM.

Lancet Respir Med. 2016 Jul;4(7):557-565. doi: 10.1016/S2213-2600(16)30033-9. Epub 2016 May 11.

Supplemental Content

Loading ...
Support Center